These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22892843)

  • 21. Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.
    Uwada J; Mukai S; Terada N; Nakazawa H; Islam MS; Nagai T; Fujii M; Yamasaki K; Taniguchi T; Kamoto T; Yazawa T
    Life Sci; 2021 Aug; 278():119554. PubMed ID: 33932444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles.
    Kim TH; Mount CW; Gombotz WR; Pun SH
    Biomaterials; 2010 Oct; 31(28):7386-97. PubMed ID: 20598741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Microfluidic Multisize Spheroid Array for Multiparametric Screening of Anticancer Drugs and Blood-Brain Barrier Transport Properties.
    Eilenberger C; Rothbauer M; Selinger F; Gerhartl A; Jordan C; Harasek M; Schädl B; Grillari J; Weghuber J; Neuhaus W; Küpcü S; Ertl P
    Adv Sci (Weinh); 2021 Jun; 8(11):e2004856. PubMed ID: 34105271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
    Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
    Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.
    Schwonzen M; Kurbacher CM; Mallmann P
    Anticancer Drugs; 2000 Oct; 11(9):681-5. PubMed ID: 11129728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
    Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
    Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
    Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
    Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
    Wang H; Li F; Du C; Wang H; Mahato RI; Huang Y
    Mol Pharm; 2014 Aug; 11(8):2600-11. PubMed ID: 24405470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
    Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
    Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
    Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
    Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells.
    Akizuki R; Maruhashi R; Eguchi H; Kitabatake K; Tsukimoto M; Furuta T; Matsunaga T; Endo S; Ikari A
    Biochim Biophys Acta Mol Cell Res; 2018 May; 1865(5):769-780. PubMed ID: 29524521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.
    Salzano G; Costa DF; Sarisozen C; Luther E; Mattheolabakis G; Dhargalkar PP; Torchilin VP
    Small; 2016 Sep; 12(35):4837-4848. PubMed ID: 27432595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of low-intensity pulsed ultrasound on doxorubicin delivery in 2D and 3D cancer cell cultures.
    Paškevičiūtė M; Januškevičienė I; Sakalauskienė K; Raišutis R; Petrikaitė V
    Sci Rep; 2020 Sep; 10(1):16161. PubMed ID: 32999381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids.
    Oktem G; Vatansever S; Ayla S; Uysal A; Aktas S; Karabulut B; Bilir A
    Oncol Rep; 2006 Feb; 15(2):335-40. PubMed ID: 16391851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.